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Background: Pancreatic cancer is a highly lethal cancer with limited diagnostic and therapeutic modalities.
Methods: To begin to explore the genomic landscape of pancreatic cancer, we used massively parallel sequencing
to catalog and compare transcribed regions and potential regulatory elements in two human cell lines derived
from normal and cancerous pancreas.
Results: By RNA-sequencing, we identified 2,146 differentially expressed genes in these cell lines that were
enriched in cancer related pathways and biological processes that include cell adhesion, growth factor and
receptor activity, signaling, transcription and differentiation. Our high throughput Chromatin immunoprecipitation
(ChIP) sequence analysis furthermore identified over 100,000 regions enriched in epigenetic marks, showing either
positive (H3K4me1, H3K4me3, RNA Pol II) or negative (H3K27me3) correlation with gene expression. Notably, an
overall enrichment of RNA Pol II binding and depletion of H3K27me3 binding were seen in the cancer derived cell
line as compared to the normal derived cell line. By selecting genes for further assessment based on this difference,
we confirmed enhanced expression of aldehyde dehydrogenase 1A3 (ALDH1A3) in two larger sets of pancreatic
cancer cell lines and in tumor tissues as compared to normal derived tissues.
Conclusions: As aldehyde dehydrogenase (ALDH) activity is a key feature of cancer stem cells, our results indicate
that a member of the ALDH superfamily, ALDH1A3, may be upregulated in pancreatic cancer, where it could mark
pancreatic cancer stem cells.
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Although pancreatic cancer is the tenth most commonly
diagnosed cancer in the U.S., it is the fourth most com-
mon cause of cancer mortality with close to 37,000
deaths per year in the U.S. [1]. The aggressive nature of
this cancer is further emphasized by the dismal five-year
survival rate of less than 5% [2]. Pancreatic ductal
adenocarcinoma (PDAC), the most common form of
pancreatic cancer, is thought to arise through a multistep* Correspondence: amundadottirl@mail.nih.gov
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reproduction in any medium, provided the orprocess involving intermediate precursor lesions known
as pancreatic intraepithelial neoplasias (PanINs) [3].
Genome-wide sequencing approaches have revealed a
complex set of somatic alterations in pancreatic tumors
such as single base mutations, amplifications, deletions
and complex rearrangements that drive cancerous growth
through specific signaling pathways [4,5]. The genes most
frequently altered in pancreatic cancer are KRAS, TP53,
CDKN2A and SMAD4, leading to an activation of growth
promoting and cell survival pathways, and inactivation of
tumor suppressors and apoptotic pathways [4].
In addition to an accumulation of somatic mutations
that affect the DNA sequence directly, epigenetic events
can lead to an increase in cell growth or survival andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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methylation and post-translational modification of his-
tone proteins are epigenetic mechanisms that regulate
gene expression in normal and cancerous cells. DNA
methylation at specific genes can increase or decrease in
cancer and is often associated with an inactivation of
tumor suppressor genes [7]. Post-translational modifica-
tion of histones mediates appropriate gene expression by
regulating access of the transcriptional machinery to the
underlying DNA [8]. Changes in DNA methylation have
been investigated in pancreatic cancer [9-11] but gen-
ome wide maps of histone modification patterns have
not been reported in this disease.
To enhance our understanding of the pancreatic can-
cer genome, we catalogued transcribed sequences
and potential functional elements in cell lines derived
from normal and neoplastic pancreatic tissues by next
generation RNA-sequencing and chromatin immunopre-
cipitation (ChIP) with massively parallel sequencing. Dif-
ferentially expressed genes and pathways were identified,
and gene expression was correlated to histone modifica-
tion patterns that mark active and repressed chromatin.Methods
Cell lines and cell culture
Two human pancreatic cell lines were purchased from
ATCC: hTERT-HPNE (derived from normal ductal
pancreatic tissue, immortalized with the TERT gene;
modal chromosome number = 46) [12,13] and PANC-1
(derived from pancreatic ductal adenocarcinoma; modal
chromosome number = 63) [14]. The hTERT-HPNE cell
line was cultured in 75% DMEM (ATCC), 25% Medium
M3 Base (Incell Corporation), supplemented with 5%
fetal bovine serum (FBS), 10 ng/ml human recombinant
EGF, 5.5 mM D-glucose (1 g/L) and 750 ng/ml puro-
mycin. The PANC-1 cell line was cultured in DMEM
(ATCC) supplemented with 10% FBS. Cells were grown
to log phase and harvested for RNA and ChIP sequen-
cing experiments at approximately 60-80% confluency.
The cell lines were harvested at passage 18 (PANC-1)
and 23 (hTERT-HPNE) after purchase from ATCC.RNA preparation
Total RNA was isolated from ~5×106 cells using the
mirVana™ miRNA isolation kit (Ambion) according to
the manufacturer’s protocol (retaining the small RNA
fraction in the pool of total RNA). DNAse treatment
was performed with TURBO DNase (Ambion); RNA
quantity was assessed by Nano Drop (Thermo Scientific)
and RNA quality by using the Agilent 2100 Bioanalyzer
(Agilent Technologies). RNA quality (RIN) scores for
RNA prepared from cell lines were > 9.0.ChIP and template preparation
Chromatin immunoprecipitation (ChIP) was performed
with the ChIP-IT™ Express kit (Active Motif ) according
to the manufacturer’s protocol. Briefly, cells were grown
to log phase and cross-linked with 1% formaldehyde for
10 minutes at room temperature. The fixation reaction
was stopped by a glycine stop solution and cells were
washed in PBS and homogenized in lysis buffer
supplemented with protease inhibitors. Shearing was
performed by sonication in a Diagenode Bioruptor
(30-sec on/off pulses for 15–20 min at high setting) to
obtain 200–500 bp DNA fragments. After centrifugation,
the supernatant was used for chromatin immunoprecipi-
tation (from ~1×107 cells each) using antibodies for:
anti-mono-methylated histone H3 at lysine 4 (H3K4
me1) (Abcam, ab8895), anti-tri-methylated histone H3
at lysine 4 (H3K4me3) (Abcam, ab12209), anti-tri-meth-
ylated histone H3 at lysine 27 (H3K27me3) (Abcam,
ab6002) and anti-RNA polymerase II (Pol II) (Abcam,
ab817). Input samples consisted of 10 μL sonicated
chromatin. For each ChIP, 20 μg sheared chromatin was
incubated overnight at 4°C on an end-to-end rotator,
with 8μg antibody, protein G magnetic beads and prote-
ase inhibitors. Finally, the ChIP and input DNA samples
were reverse cross-linked, treated with proteinase K
and purified with the QIAquick PCR Purification Kit
(Qiagen).
Library preparation and sequencing
For mRNA-seq sample preparation, the mRNA-seq
Sample Prep Kit (Illumina) was used according to the
manufacturer’s protocol. Briefly, 1 μg total RNA was
used for polyA mRNA selection using Sera-mag oligo
(dT) beads, followed by thermal fragmentation at 94°C.
First strand cDNA synthesis was performed using Super-
script II reverse transcriptase and random primers.
Second strand synthesis was performed using DNA
Polymerase I followed by end repair with T4 DNA poly-
merase, Klenow DNA polymerase and T4 polynucleotide
kinase (PNK). Finally, the double-stranded cDNA was
ligated to Illumina paired-end (PE) adaptors and size se-
lection performed for fragments in the 350±25 bp range.
Libraries were amplified using Phusion DNA polymer-
ase, followed by purification with the QIAquick PCR
Purification Kit (Qiagen). Amplified libraries were di-
luted with Elution Buffer to a final concentration of 10
nM and run at a concentration of 4–6 pM on two Gen-
ome Analyzer (GAII) lanes.
MicroRNA-seq sample preparation was performed
with the Small RNA v1.5 sample prep Kit (Illumina)
according to the manufacturer’s protocol. Briefly, 3′ and
5′ small RNA adapters were ligated to 10 μg total RNA
followed by reverse transcription with Superscript II and
amplification using Phusion DNA polymerase. This was
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range and measurement using a Bioanalyzer. Amplified
miRNA-seq libraries were diluted with Elution Buffer to
a final concentration of 10 nM and run at a concentra-
tion of 4–6 pM on one Genome Analyzer (GAIIx) lanes.
For ChIP-seq sample preparation, pooled ChIP reac-
tions (10 ng) were used to prepare a single library using
the ChIP-seq Sample Prep Kit (Illumina) according to
the manufacturer’s protocol. Briefly, DNA ends were
repaired with T4 DNA polymerase, Klenow polymerase
and T4 PNK. The Klenow fragment (3′ to 5′ exo minus)
was then used to generate a protruding 3′ A base and
adapter oligos were ligated using DNA ligase. ChIP
DNA in the 200±25 bp range was recovered and ampli-
fied using Phusion polymerase. Library concentration
was assessed using a Bioanalyzer. Amplified libraries
were diluted with Elution Buffer to a final concentration
of 10 nM and run at a concentration of 4–6 pM on 2–3
Genome Analyzer (GAII or GAIIx) lanes. All next-
generation sequencing was carried out at the National
Cancer Institute’s Center for Cancer Research Sequen-
cing Facility operated by the Advanced Technology
Program of SAIC-Frederick, Inc. (Gaithersburg, MD).
Sequence alignment and analysis
mRNA-sequencing: paired-end RNA-seq was repeated
twice for each cell line to obtain reliable numbers of se-
quence reads (Additional file 1: Table S1A). The median
number of reads (35 bp) generated per paired-end ex-
periment was 8.9 M (8.6 to 11.2 M). Total reads were
combined for each cell line: 19,778,468 for the hTERT-
HPNE and 17,769,249 for PANC-1 cells. No significant
difference was observed in the number of reads gener-
ated between the two cell lines (Student’s t-test, P=0.53).
Paired-end reads were mapped to the RefSeq database
(National Center for Biotechnology Information (NCBI)
build 37) using the Burrows-Wheeler Aligner (BWA)
software with default parameters that allow up to 3
alignments for each read and up to 2 mismatches for the
seed sequence (the first 25 bp of each read) [15]. Reads
that failed to map to RefSeq were mapped to the
Ensembl database, which includes additional transcripts
and pseudogenes [16]. Remaining unmapped reads were
mapped to the human genome assembly (NCBI build
37). The analysis pipeline is shown in Additional file 2:
Figure S1. Gene expression was calculated in reads per
kilobase of exon per million mapped sequence reads
(RPKM) [17]. After filtering, we included 11,249 genes
expressed above 1 RPKM in at least one cell line for fur-
ther analysis. The edgeR package was used to identify
genes that were differentially expressed in the two cell
lines using total tag count values for each gene [18].
Data was normalized using the weighted trimmed mean
of log-ratio values (using hTERT-HPNE as a reference)to account for library size; statistical analysis was
performed using the Fisher’s exact test. We considered
genes to be differentially expressed between cell lines
when the Benjamini-Hochberg false discovery rate
(FDR) was less than 0.05 and the fold change difference
in expression was equal to or greater than 3.
miRNA-sequencing: After trimming adaptor sequences
and filtering low-quality reads, a total of 9,262,094 and
18,006,865 single-end short (22 bp) sequence reads were
obtained from PANC-1 and hTERT-HPNE cells, respect-
ively (Additional file 1: Table S1B). The miRNAkey soft-
ware [19] was used to remove adaptor sequence from
the 3′-ends of reads, to map raw reads to the miRBase
mature database (release 16) [20], calculate normalized
RPKM expression values and quantify differentially
expressed miRNAs. Two hundred and fifty eight miRNA
genes were detected at 1 RPKM or higher in at least one
of the cell lines. Genes were considered differentially
expressed with a fold change difference ≥ 3 and a
Bonferroni corrected Chi-square P-value < 0.05.
Pathway enrichment analysis: Gene set enrichment ana-
lysis of differentially expressed mRNA and miRNA genes
was performed based on KEGG (Kyoto Encyclopedia of
Genes and Genomes) [21] and GO (Gene Ontology)
[22] annotations using GOseq, as it accounts for the
bias of over-detection of differential expression for long
and highly expressed transcripts [23]. The Wallenius ap-
proximation method with Benjamini-Hochberg corrected
P-values was used to determine enriched pathways; and
an FDR < 0.05 was considered significant.
ChIP-sequencing: ChIP-seq single-end experiments
were run on 2–3 lanes to obtain an adequate number of
reads (Additional file 1: Table S1C). Matching input
DNA was sequenced to obtain a reference for each cell
line. The total number of short (35 bp) reads generated
per lane varied from 4,509,035 to 27,577,446 with a me-
dian of 19,279,525. Raw reads were combined for each
histone modification mark and RNA Pol II as well as for
input DNA for each of the cell lines. No significant dif-
ference was observed in the number of reads generated
in the two cell lines for the different histone modifica-
tion marks or for RNA Pol II (Student’s t-test, P-value
range: 0.17-0.83). Alignment to the human genome as-
sembly (NCBI build 37) was performed using Bowtie,
allowing for up to 2 mismatches and only one (best)
alignment [24]. The SICER software [25] was used to
identify qualified peaks (islands) of histone and Pol II
binding by comparing sequence reads from immunopre-
cipitated and input DNA. A consolidating window size
of 200 bps was used, a gap size of 200 bps (H3K4me1,
H3K4me3 and Pol II) or 600 bps (H3K27me3), effective
genome size of 81%, ratio of enrichment between experi-
mental data (PANC-1) and control (hTERT-HPNE) ≥3
and an FDR <0.05. Differentially enriched epigenetic
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SICER-df function. A cis-regulatory element annotation
system (CEAS) was used to attain summary statistics on
ChIP enrichment peaks based on location in promoters,
gene bodies or nongenic regions using the RefSeq data-
base [26].
Integration of ChIP-seq and RNA-seq
Genes were divided into quartiles based on digital expres-
sion levels (RPKM values) for each cell line. Global profil-
ing curves were generated for genes in each of the quartile
groups by plotting the read distributions (tags were binned
into 25 bps bins and trimmed based on Poisson distribu-
tion) of different histone modification marks and RNA Pol
II within 5,000 bp up- and downstream of transcription
start sites (TSS) for RefSeq genes.
Genomic copy number alterations
To assess if a bias existed in read mapping for ChIP-Seq
because of chromosomal copy number gains or losses,
we extracted DNA (Gentra Puregene Tissue Kit, Qiagen)
from the hTERT-HPNE and PANC-1 cell lines, and ge-
notyped at NCI’s Cancer Genomics Research Laboratory
using the Illumina Human Hap 1M-Duo chip. The
Illumina GenomeStudio software was used to compute
affinity-normalized probe intensities (normalized geno-
type probe intensities, log R ratio (LRR) and B allele fre-
quency (BAF)), quality scores and to call genotypes.
Renormalized (quantile) LRR and BAF values were then
analyzed using a custom software pipeline, R-Gada [27],
to detect whole-chromosome and segmental events as
previously described [28].
We only observed chromosomal copy number alter-
ations in the PANC-1 cell line but not in the hTERT-
HPNE cells. Adjacent events were merged if they had an
identical state and distance between segments was <1
Mb. Each event was then classified as copy number gain,
loss or copy neutral loss of heterozygosity (CNLOH).
Since we observed only 200 (0.49%) regions enriched for
RNA Pol II binding and 41 (0.57%) regions enriched for
H3K27me3 binding in regions that were lost in PANC-1
cells, these were excluded from further analysis. To esti-
mate a possible bias in mapping, we then calculated the
number of regions enriched for RNA Pol II and
H3K27me3 binding in the PANC-1 cells per 1 Mb for
each autosomal chromosome for gain, CNLOH and copy
neutral events. For interclass, unpaired comparisons, we
used the Mann–Whitney U-test to assess differences in
the distribution of genomic regions enriched for RNA
Pol II and H3K27me3 binding in the PANC-1 cells.
To assess if genes selected for replication by TaqMan
expression analysis (see below) were located in regions
of copy number gain or loss, we also genotyped the
following cell lines and assessed chromosomal abnor-malities as described above: AsPC-1, BxPC-3, Capan-1,
CFPAC-1, Hs 766T, SU.86.86 and SW 1990.
Assessment of differential mRNA expression analysis
using Real-Time qPCR
An assessment of differential expression levels was
attempted for 4 genes using custom mRNA Taqman ex-
pression assays (Applied Biosystems): ALDH1A3 (Hs001
67476_m1), ITGBL1 (Hs00191224_m1), NFE2L3 (Hs00
852569_g1) and SEMA4B (Hs00384240_m1). Fresh fro-
zen pancreatic tissue samples (10 normal and 10 tumor
derived) were obtained from the Mayo Clinic in Roches-
ter MN (approved by the Institutional Review Board of
the Mayo Clinic). All tumors were from patients diag-
nosed as adenocarcinoma of the pancreas, with tumor
percentages ≥70%; all normal derived samples were adja-
cent to tumors (unmatched to tumors), confirmed by a
pathologist to be normal by pathology and with ≥80%
epithelial component. Eleven additional pancreatic can-
cer cell lines were purchased from ATCC and cultured
according to their guidelines: AsPC-1, BxPC-3, Capan-1,
Capan-2, CFPAC-1, Hs 766T, HPAF-II, MIA PaCa-2,
Panc 10.05, SU.86.86 and SW 1990. An additional 39
pancreatic cancer cell lines (see Additional file 3: Table S6
for names of cell lines and references) were kindly pro-
vided by Dr. Udo Rudloff, Surgery Branch, NCI, NIH, and
maintained in DMEM with 10% FBS. Frozen tissue sections
(10 μm cut in at −20°C in a Cryostat) and cell lines (log
phase) were harvested for RNA isolation as described
above. Total RNA was reverse transcribed using Super-
script III first-strand synthesis kit (Invitrogen). RT-qPCR
was performed in triplicates using Taqman gene expres-
sion Master Mix (Applied Biosystems) and a 7900HT se-
quence detecting system (Applied Biosystems). The Cy0
method was used to obtain the best fit estimators of reac-
tion parameters for real-time PCR data [29]. The ΔΔCt
method was used to calculate expression values by nor-
malizing to the geometric mean of two housekeeping
genes (B2M #Hs00187842_m1 and PPIA #Hs9999990
4_m1; Applied Biosystems).
Results
Using a genome-wide approach, we have assessed global
gene expression profiles and regulatory elements in two
cell lines derived from normal pancreatic ducts (hTERT-
HPNE) and pancreatic ductal adenocarcinoma (PANC-
1) by massively parallel sequencing-by-synthesis.
Transcriptome analysis of pancreatic cell lines by mRNA-
seq and miRNA-seq
The total number of paired-end mRNA-sequence reads
generated for each cell line is listed in Additional file 1:
Table S1A. We constructed our mRNA-seq analysis
pipeline to align reads sequentially to the RefSeq,
Jia et al. BMC Medical Genomics 2013, 6:33 Page 5 of 13
http://www.biomedcentral.com/1755-8794/6/33Ensembl and Human Genome (NCBI build 37) data-
bases using BWA [15] (Additional file 2: Figure S1). By
comparing the cancer derived PANC-1 cells to the nor-
mal pancreatic tissue derived hTERT-HPNE cells, we
identified 1,983 differentially expressed mRNA genes at
a threshold of 3-fold difference or greater (Additional
file 4: Table S2). Of these genes, 971 were expressed at
higher levels and 1,012 at lower levels in the cancer de-
rived cells compared to the normal derived pancreatic
cells. Examples of mRNA genes that were expressed at
higher levels in the PANC-1 cell line include growth fac-
tors, receptors, and signaling molecules such as SHH,
PDGFB, SMAD3, AKT2 and multiple WNT genes
(WNT6, WNT7B, WNT9A and WNT10A). Genes
expressed at lower levels in the PANC-1 cells include
CDKN1A, CDKN2B, HHIP, PDGFRA, PDGFRB and
MMP1. In addition, many genes encoding extracellular
matrix (ECM) proteins and their receptors (integrins)
were differentially expressed in the two cell lines.
The total number of single-end miRNA sequence
reads is listed in Additional file 1: Table S1B. We aligned
reads to miRNA genes in the miRBase mature database,
using miRNAKey [19]. Of the 258 miRNA genes
expressed at 1 RPKM or higher, 128 were expressed at
higher levels and 35 at lower levels in the cancer derived
PANC-1 as compared to normal derived hTERT-HPNE
cell line (Additional file 5: Table S3). Differential miRNA
expression levels included higher levels of MIR767,
MIR135B, MIR1269, MIR182, MIR183, and MIR203 and
lower levels of MIR494, MIR424, MIR381, MIR452, and
MIR155 in PANC-1 cells.
We used KEGG [21] and GO [22] enrichment analysis
to categorize differentially expressed mRNA and miRNATable 1 KEGG pathway enrichment analysis for mRNA and m
derived pancreatic cell lines
KEGG pathway ID KEGG pathway name
05200 Pathways in cancer
04510 Focal adhesion
04512 ECM-receptor interaction
04060 Cytokine-cytokine receptor interaction
04310 Wnt signaling pathway
04360 Axon guidance
04514 Cell adhesion molecules (CAMs)
04020 Calcium signaling pathway
04080 Neuroactive ligand-receptor interaction
05412 Arrhythmogenic right ventricular cardiomyopath
05414 Dilated cardiomyopathy
05410 Hypertrophic cardiomyopathy (HCM)
04640 Hematopoietic cell lineage
05217 Basal cell carcinoma
04610 Complement and coagulation cascades
KEGG pathway ID numbers are listed and statistical significance is shown by P valuegenes into biologically relevant pathways and processes.
The fifteen significantly enriched KEGG pathway cat-
egories included: pathways in cancer, focal adhesion,
ECM-receptor interaction, Wnt signaling and cell adhe-
sion molecules (Table 1). An enrichment of genes related
to cardiomyopathy was also noted, but the list of genes
overlapped considerably with two other pathways: focal
adhesion and ECM-receptor interaction. Similarly, we
detected significant enrichment of 56 GO biological
process categories including: signal transduction, cell dif-
ferentiation and cell adhesion (Additional file 6: Table
S4). We also detected 25 GO molecular function cat-
egories including: signal transducer activity, receptor
activity, transcription factor activity, calcium ion bind-
ing, actin binding and growth factor activity (Additional
file 7: Table S5).Epigenome analysis of normal and cancer derived
pancreatic cell lines by ChIP-seq
To evaluate genome-wide distribution of epigenetic
marks that associate with active or repressed expression,
we performed ChIP-seq in the PANC-1 and hTERT-
HPNE cell lines using antibodies specific for three his-
tone modification marks: H3K4me1, H3K4me3 and
H3K27me3, and for RNA Pol II. Reads (Additional file 1:
Table S1C) were aligned to the human genome (NCBI
build 37) using Bowtie [24]. Binding sites for histone
modification marks and RNA Pol II were identified by
comparing immunoprecipitated chromatin with input
DNA using SICER [25]. The total number of all binding
sites for H3K4me1, H3K4me3, H3K27me3, and RNA
Pol II identified in each cell line at a FDR of ≤0.001 wasiRNA genes differentially expressed in tumor and normal
P-value FDR # of genes
5.40 × 10-06 1.15 × 10-04 69
1.05 × 10-11 1.12 × 10-09 61
1.11 × 10-14 2.37 × 10-12 36
3.43 × 10-07 1.22 × 10-05 36
6.26 × 10-05 8.75 × 10-04 36
3.82 × 10-06 9.05 × 10-05 33
2.27 × 10-08 9.67 × 10-07 29
1.47 × 10-05 2.61 × 10-04 29
1.78 × 10-08 9.47 × 10-07 26
y (ARVC) 1.44 × 10-08 9.47 × 10-07 24
3.82 × 10-06 9.05 × 10-05 22
2.64 × 10-06 8.02 × 10-05 21
1.47 × 10-05 2.61 × 10-04 16
6.58 × 10-05 8.75 × 10-04 15
1.01 × 10-04 1.27 × 10-03 10
s and FDR values.
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hTERT-HPNE cell line (Additional file 1: Table S1C).
The most prominent binding sites in promoters (up to 3
kb upstream of known transcription start sites) were seen
for H3K4me3 (26.6% of all sites in the hTERT-HPNE cell
line and 27.3% in the PANC-1 cell line), in accord with its
role in activation of gene expression. A similar pattern of
binding sites was seen for H3K4me3 and RNA Pol II in
the two cell lines, particularly in exons (range 2.7-3.1%),
untranslated regions (range 2.8-4.0%) and introns (41.2-
41.4% for RNA Pol II and 49.2-51.9% for H3K4me3).
Similar overall binding patterns were noted for H3K4me1
and H3K27me3 in both cell lines with regard to promoters
(4.1-7.6%), exons (0.9-1.8%) and untranslated regions
(0.7-1.4%). A greater number of intronic binding sites
were seen for H3K4me1 (54.3-56.7%) as compared to
H3K27me3 (36.8-38.1%), and fewer sites were noted in
distal intergenic regions for H3K4me1 (28.9-37.6%) as


















































































Figure 1 Distribution of histone modification marks and RNA Polyme
RefSeq genes. Genes were divided into four categories according to gene
low (D). Density traces for histone modification sequence tags were then g
four groups. Density traces are labeled in green for H3K4me1, red for H3K4
Results are shown for the PANC-1 cell line; similar results were seen for theIntegration of ChIP-seq and mRNA-seq
To correlate enrichment for histone modification marks
to gene expression, we divided genes into four equal
subsets based on digital gene expression levels (in
RPKM) from highest to lowest. We then summarized se-
quence reads from ChIP-seq relative to transcription
start sites (TSS) (+/− 5,000 bps) for all RefSeq genes
(Figure 1 for the PANC-1 cell line and Additional file 9:
Figure S3 for the hTERT-HPNE cell line) to assess their
patterns in promoter elements of genes expressed at dif-
ferent levels. Read density for H3K4me1 and H3K4me3
was increased surrounding the TSS of highly expressed
genes in both cell lines, especially for the latter histone
mark. The distribution of reads is bimodal, with an in-
creased number of reads upstream and downstream of
the TSS and a valley in-between. The peaks are located
at approximately 600–800 bps upstream and 1,200-1,400
bps downstream of the TSS for H3K4me1 and at ap-
proximately 300–400 bps up- and downstream of the
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Figure 2 Distribution of the histone modification marks and RNA Polymerase II binding sites relative to transcriptional start sites (TSS)
for RefSeq genes. Genes were divided into four categories based on digital gene expression (RPKM values) from high to very low. Sequence
reads were then graphed relative to the TSS for each group. Density traces are labeled in blue for genes expressed at the highest levels, red for
medium levels, green for low levels and purple for very low levels (see panel insert). Results are shown for the PANC-1 cell line (panels (A) for
H3K27me3, (C) for H3K4me3, (E) for H3K4me1 and (G) for RNA Pol II) and for the hTERT-HPNE cell line (panels (B) for H3K27me3, (D) for
H3K4me3, (F) for H3K4me1, and (H) for RNA Pol II). Note the “dip” in H3K27me3 sequence tags around the TSS of highly expressed genes in
PANC-1 cells.
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expressed genes with a peak of greatest density right
around the TSS. Genes expressed at lower levels gradually
lost binding of histones modified at lysine 4 and RNA Pol
II (Figure 1, Figure 2, Additional file 9: Figure S3). In
contrast, these genes are characterized by a relatively high
density of reads for H3K27me3 with the greatest en-
richment at approximately 200–300 bps downstream of
the TSS (Figure 2A and B). Notably, when comparing
epigenetic marks across the two cell lines, the greatest
fraction of peaks enriched ≥3 fold in the PANC-1 cells
was seen for RNA Pol II (71.8% increased, 28.2% de-
creased) and the greatest number of peaks decreased ≥3
fold in the PANC-1 cells was seen for the negative
H3K27me3 histone modification mark (81.0% decreased,
19.0% increased), implying that the cancer cells may
be better poised for active transcription (Table 2A).
This appears to happen on a genome wide level and
can be seen in Figure 2 where H3K27me3 sequence
tags “dip” around the TSS of highly expressed genes in the
PANC-1 cell line (Figure 2A) but not the hTERT-HPNE
line (Figure 2B).
To verify that this differential enrichment in RNA Pol
II and H3K27me3 binding sites was not caused by a bias
in read mapping due to differences in DNA copy num-
ber, we genotyped the cell lines using the Illumina
Human Hap 1M chip. We noted chromosomal alter-
ations in the PANC-1 cells but not in the hTERT-HPNE
cells. To assess mapping bias, we compared binding sitesTable 2 Characteristics of epigenetic marks that were increas
to the hTERT-HPNE cell line
A. Epigenetic marks that were enriched or depleted in PANC-1 as comp
Increased in PA
Mark Fold change # Increased
RNA Pol II ≥ 3 42,809
H3K4Me3 ≥ 3 4,434
H3K4me1 ≥ 3 13,999
H3K27Me3 ≥ 3 2,474









P value 1.08 x 10
FDR 3.16 x 10
A. Number and percentages of epigenetic marks that were increased or decreased
B. Epigenetic marks in the ALDH1A3 gene are listed with location (NCBI build 37) of
significance values (P value and False Discovery Rate, FDR).for RNA Pol II and H3K27me3 in genomic regions in
the PANC-1 cells showing either gain or copy neutral
loss of heterozygosity (CNLOH) relative to copy neutral
genomic regions. We did not observe statistically signifi-
cant differences in the distribution of regions enriched
for RNA Pol II binding in regions showing copy number
gain (P=0.52) or CNLOH (P=0.11) as compared to copy
neutral genomic regions. Similarly, we did not observe
differences in the distribution of regions enriched for
H3K27me3 binding in regions showing gain (P=0.61) or
CNLOH (P=0.89) as compared to copy neutral genomic
regions, suggesting that the observed differences in epi-
genetic marks in the two cell lines are not due to a dif-
ference in copy number alterations.
Overexpression of ALDH1A3 in pancreatic cancer cell
lines and tumors
We used the transcriptome and epigenome data de-
scribed above to select genes for assessment of expres-
sion differences in independent sets of normal and
tumor derived pancreatic tissue samples and cell lines.
We based our selection of genes on the strong differ-
ences in RNA Pol II and H3K27me3 binding sites in the
two cell lines by applying the following criteria: 1.)
located within 5 kb of a region enriched ≥ 3 fold for
RNA Pol II binding in the PANC-1 cells, 2.) located
within 5 kb of a region enriched ≥ 3 fold for H3K27me3
binding in the hTERT-HPNE cells, and 3.) showed ≥ 3
fold increased expression in the PANC-1 as compared toed or decreased over 3 fold in the PANC-1 as compared
ared to hTERT-HPNE pancreatic cells
NC-1 cells Decreased in PANC-1 cells














-13 8.55 x 10-24
-13 1.27 x 10-22
over 3 fold in the PANC-1 as compared to the hTERT-HPNE cell lines.
the respective epigenetic mark, normalized read counts, fold change and
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(labeled in bold in Additional file 4: Table S2). We then
selected 4 genes from this list based on varying levels of ex-
pression differences and location in genomic regions that
either showed copy-number gain (ALDH1A3, SEMA4B) or
did not (ITGBL1, NFE2L3) in PANC-1 cells. We first
assessed gene expression by RT-qPCR in 10 normal and 10
tumor derived pancreatic tissue samples as well as in 11
additional pancreatic cancer cell lines. By selecting differ-
entially expressed genes that were also enriched in positive
marks and depleted in negative marks we confirmed differ-
ential expression of one of the four genes, ALDH1A3, in
this set of tumor and normal derived pancreatic tissues
and cell lines (Figure 3, panels A and B). This gene was
expressed on average 1.93 fold higher in the tumor derived
samples as compared to the normal derived pancreatic tis-
sue samples (PMann–Whitney U test=0.034), and 3 of the 10
tumor samples had over 3 fold higher expression than the
average of the normal samples (range 3.32-4.10). The
ALDH1A3 gene was expressed on average 1,308 fold
higher in the tumor cell lines as compared to the normal
derived hTERT-HPNE cells, and 23.5 fold higher in the
tumor cell lines as compared to the average of the normal
derived tissue samples. The difference between ALDH1A3
expression levels in the tumor derived cell lines as com-
pared to the tissue samples may be due to the higher de-
gree of cellular heterogeneity in the latter set. Interestingly,
by analyzing copy number alterations, we noted that its ex-
pression is increased in cell lines showing copy number
gain of the genomic region it resides in (PANC-1, SU.86.86
and BxPC-3) as well as in cell lines without gain (Hs 766T,
AsPC-1, Capan-1, SW 1990 and CFPAC-1) as shown in
Figure 3B. We confirmed differential expression for the
three other genes in the hTERT-HPNE and PANC-1 cell
lines by RT-qPCR, but did not observe significantly differ-
ential expression in the larger set of cell lines and tissue
samples. A second validation in an independent set of 39
additional pancreatic cancer cell lines (Additional file 3:
Table S6) showed that ALDH1A3 was expressed on average
1,630 fold higher in the tumor cell lines as compared to
hTERT-HPNE cells, and 78.5 fold higher in the tumor cell
lines as compared to the average of the normal derived tis-
sue samples (Figure 3C). Increased RNA Pol II binding
was seen in the promoter region of ALDH1A3 (12.39 fold),
and decreased H3K27me3 binding (0.23 fold) in a region
overlapping and surrounding exons 7 and 8, in the PANC-
1 as compared to the hTERT-HPNE cells (Table 2B). In
addition, binding of the negative mark H3K27me3 featured
prominently over the first half of the gene in hTERT-
HPNE cells (Additional file 10: Figure S4).
Discussion
Generating global datasets of transcribed sequences and
epigenetic marks can form a foundation for genomicand functional investigations of the molecular mecha-
nisms underlying specific cancers. Such datasets have
been generated for many tissue types as part of the
ENCODE project [30]. To begin to establish genomic
datasets for the pancreas we analyzed expressed se-
quences and signatures of functional elements in normal
and pancreatic cancer derived cell lines by massively
parallel sequencing. We used a diploid cell line derived
from normal pancreatic ducts and immortalized with
the TERT gene, hTERT-HPNE, and a commonly used
hypertriploid pancreatic ductal carcinoma derived cell
line, PANC-1, for our studies. In this process, we identi-
fied differentially expressed genes that define pathways
and cellular processes important for cancer, such as
growth factor and receptor activity, signal transduction,
focal adhesion, ECM-receptor interaction and cell differ-
entiation. Enrichment of genes in these pathways reiter-
ates the increased growth potential and diminished
adhesive properties associated with the development and
progression of pancreatic cancer.
Many of the differentially expressed genes encode
ligands, receptors and signaling molecules in the wing-
less and sonic hedgehog signaling pathways, implicated
in embryonic development and particular cancers, in-
cluding that of the pancreas [31-33]. Genes important
for focal adhesion and extracellular matrix receptor
interaction were also prominent among differentially
expressed genes featuring numerous integrin, collagen
and laminin subtypes possibly indicating an underlying
potential for altered proliferation and interaction with
the microenvironment of the tumor derived cell line in
an in vivo setting. MicroRNA expression has not been
assessed before in pancreatic cancer by next generation
sequencing methods. Our results in the two cell lines
agree with previously published data on the upregulation
of MIR93, MIR95, MIR135B, MIR181C, MIR181D,
MIR182, MIR183, MIR190, MIR196B and MIR203, and
downregulation of MIR20A and MIR29C in pancreatic
intraepithelial neoplasms (PanIns) or pancreatic adeno-
carcinomas (PDACs) as compared to normal pancreatic
tissue [34-36]. In agreement, we noted substantially
higher (from 6 to over 200 fold) expression of the
former group of genes and lower (3–18 fold) expression
of the latter group in our dataset. MIR135B, MIR182
and MIR183 are overexpressed in a wide range of other
cancer types such as bladder, colon, prostate cancer and
glioma [37-41]. In addition, we noted differential expres-
sion of miRNA genes not previously reported to be
deregulated in cancer. Some of the largest differences
were observed for MIR767 and MIR1269, both absent in
the hTERT-HPNE cells but highly expressed in the can-
cer derived PANC-1 cells. The function of MIR767 and
MIR1269 is largely unknown although the latter may be
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Figure 3 (See legend on next page.)
Jia et al. BMC Medical Genomics 2013, 6:33 Page 10 of 13
http://www.biomedcentral.com/1755-8794/6/33
(See figure on previous page.)
Figure 3 Expression of the ALDH1A3 gene in pancreatic cell lines and tissue samples. Expression levels for ALDH1A3 were determined by
RT-qPCR in (A) normal derived pancreatic tissue samples (N-1 though N-10) and tumor derived pancreatic tissue samples (T1 through T10), as
well as (B) in pancreatic normal (n=1) and tumor (n=12) derived cell lines. Expression levels were normalized to the geometric mean of B2M and
PPIA and are shown in arbitrary units (A.U.). Chromosomal gain of the ALDH1A3 gene region is indicated below panel (B) as G: copy number gain,
N: no gain. Copy number alterations were not assessed for cell lines marked with “–“. (C) ALDH1A3 expression levels were assessed in additional
pancreatic cancer cell lines (n=39) by RT-qPCR.
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suggesting that altered miRNA expression contributes to
cancerous growth in the pancreas and provide new can-
didate miRNA genes that require validation in larger
sample sets of normal and cancerous pancreatic tissues.
Epigenomic assessment of histone modification pat-
terns revealed an enrichment of mono- and tri-
methylated H3K4 in promoters that was highest in
actively transcribed genes and gradually lost with lower
expression. The transcriptional start site of actively
transcribed genes was occupied by RNA polymerase,
surrounded by a layer of nucleosomes with tri-
methylation at H3K4 and an outer core of nucleosomes
with mono-methylation at H3K4. Trimethylation at
H3K27 showed an inverse correlation with gene expres-
sion. This pattern of modification marks is in accord-
ance with the activating and silencing effects associated
with these histone modifications in other cell types
[43,44]. Notably, an overall depletion of H3K27me3
marks and enrichment of RNA Pol II sites was seen in
the cancer derived cell line, as compared to the normal
derived cell line, indicating a possible mechanism of gen-
eral alleviation of negative epigenetic regulation in pan-
creatic cancer. By focusing on this apparent difference
between epigenetic marks in the two cell lines when
selecting genes for further examination, we confirmed
higher levels of ALDH1A3 gene expression in an inde-
pendent set of tumor derived pancreatic tissues and cell
lines in comparison to normal derived pancreatic sam-
ples. Of note is that of the genes selected for further as-
sessment, all four showed very similar results in the
initial set of cell lines using RT-qPCR, whereas only one
showed a similar expression difference in the additional
sample sets analyzed. This is probably due to the small
initial sample set. Validation in a second larger set of
pancreatic cancer cell lines confirmed higher expression
levels of ALDH1A3 as compared to the normal derived
cell line and normal derived tissue samples. A limitation
of our study is the small number of samples, especially
for normal derived pancreatic cell lines and for normal
and tumor derived tissue samples.
A general function for members of the aldehyde de-
hydrogenase (ALDH) superfamily is to serve as detoxifi-
cation enzymes by converting aldehydes to carboxyl
acids (for review see [45]). The different ALDH
subfamilies and their members have additional catalyticfunctions; the ALDH1A family is responsible for the
conversion of retinaldehyde to retinoic acid (RA) and its
three members (ALDH1A1 through ALD1A3) are thus
important regulators of RA signaling. Increased aldehyde
dehydrogenase activity is commonly seen in many can-
cer types where it appears to specifically mark cancer
stem cells [46,47]. These cells tend to be highly
tumorigenic and invasive, and are often resistant to con-
ventional therapy [48]. The presence of aldehyde de-
hydrogenase positive cells in tumor from patients with
pancreatic cancer has been associated with decreased
survival, and ALDH1A1 expression (ALDH1A3 was not
tested) correlated with invasion of pancreatic cancer cell
lines [49]. Of the 19 ALDH isoforms, ALDH1A1 has
most often been linked to the increased ALDH activity
of cancer stem cells [50]. However, ALDH1A3 expres-
sion has been shown to correlate better with aldehyde
activity in breast cancer stem cells than ALDH1A1 ex-
pression, and correlate with tumor grade, stage and me-
tastasis [51]. Although we confirmed increased mRNA
levels of ALDH1A3 in an independent set of pancreatic
tissue samples and two series of cell lines, our finding
should be validated in additional sample sets to thor-
oughly investigate the relationship between ADH1A3,
cancer stem cells and pancreatic cancer.Conclusion
The high resolution and read depth of next generation
sequencing has allowed us to accurately quantify gene
expression and locate epigenetic marks, thus enabling a
detailed analysis of the pancreatic cancer genome. Al-
though limited by a small set of samples, this study has
thoroughly catalogued the transcriptome and epigenome
of two pancreatic cell lines, confirmed previous genes
and pathways deregulated in pancreatic cancer and gen-
erated a series of hypotheses worth following-up in fu-
ture studies to investigate key events in pancreatic
carcinogenesis.Additional files
Additional file 1: Table S1. Number of reads generated by mRNA-seq
(A), miRNA-Seq (B), and ChIP-seq (C) experiments and their alignment
characteristics. The number of peaks from each ChIP-seq experiment is
shown in (C).
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http://www.biomedcentral.com/1755-8794/6/33Additional file 2: Figure S1. RNA-seq analysis pipeline for read
alignment and digital gene expression quantification.
Additional file 3: Table S6. Additional cell lines used for ALDH1A3
expression assessment by RT-qPCR. Names of pancreatic cancer cell lines,
references and additional information on how they were obtained.
Additional file 4: Table S2. Differentially expressed mRNA genes in
tumor and normal derived pancreatic cell lines. mRNA genes with a 3
fold or greater expression difference (n=1,983) are listed, as are expres-
sion values in RPKM and FDR values. Genes that are expressed ≥3 fold
higher in the PANC-1 cells, located within 5 kb of regions enriched ≥3
fold in RNA Pol II binding in the PANC-1 cells, and enriched ≥3 fold in
H3K27me3 binding in the hTERT-HPNE cells are marked in bold text.
Additional file 5: Table S3. Differentially expressed miRNA genes in
tumor and normal derived pancreatic cell lines. miRNA genes with a 3
fold or greater expression difference (n=163) are listed, as are expression
values in RPKM and FDR values.
Additional file 6: Table S4. GO analysis for enrichment of biological
processes (GO BP) for mRNA and miRNA genes differentially expressed in
tumor and normal derived pancreatic cell lines. Statistical significance is
shown by P values and FDR values.
Additional file 7: Table S5. GO analysis for enrichment of molecular
function (GO MF) for mRNA and miRNA genes differentially expressed in
tumor and normal derived pancreatic cell lines. Statistical significance is
shown by P values and FDR values.
Additional file 8: Figure S2. Distribution of histone modification peaks
and RNA Pol II binding sites according to locations within promoters,
regions downstream of genes, 5′ and 3′ untranslated regions (UTR),
coding exons, introns and distal intergenic regions of the genome for
the hTERT-HPNE (A) and PANC-1 (B) cells by analysis with the CEAS
software.
Additional file 9: Figure S3. Distribution of histone modification marks
and RNA Polymerase II binding sites according to gene expression levels
for RefSeq genes in the hTERT-HPNE cell line. Genes were divided into
four categories according to gene expression values (RPKM) from high
(A), medium (B), low (C) to very low (D). Density traces for histone
modification sequence tags were then graphed according to the start of
transcription (TSS) for each of the four groups. Density traces are labeled
in green for H3K4me1, red for H3K4me3, blue for H3K27me3 and purple
for Pol II.
Additional file 10: Figure S4. Distribution of sequence reads for RNA
Pol II and H3K27me3 in the ALDH1A3 gene in PANC-1 and hTERT-HPNE
cells. Note increased RNA Pol II binding in the promoter of ALDH1A3 in
PANC-1 cells, and increased H3K27me3 binding in first half of the gene in
the hTERT-HPNE cells.
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